Dr. Hallahan’s research focuses on identifying new molecular targets for cancer therapy and developing drugs that improve cancer response to radiation therapy while minimizing the effect on normal tissues. He has published scientific articles about translational research-driven radiotherapy treatment for cancer. He is the PI on NCI (R01, R29, R21, P50) with a focus on the development of targeted therapeutics combined with ionizing radiotherapy, novel compounds in radioprotection normal tissues.

http://radonc.wustl.edu/index.aspx